SpyGlass Pharma Prices 9.375M Shares at $16.00
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2d ago
0mins
Should l Buy SGP?
pyGlass Pharma priced 9.375M shares $16.00, the midpoint of the $15.00-$17.00 range. Jefferies, Leerink, Citi and Stifel are acting as joint book running managers for the offering. SpyGlass Pharma is a late-stage biopharmaceutical company whose drug delivery technology is designed to be used with various well-established, approved medicines, including bimatoprost and other small molecules, providing flexibility to potentially treat a range of conditions in the front and back of the eye.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SGP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SGP
Wall Street analysts forecast SGP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SGP is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 16.000
Low
Averages
High
Current: 16.000
Low
Averages
High
No data
About SGP
SpyGlass Pharma Inc is a United States-based ophthalmic drug delivery company. The Company is focused on developing and commercializing long-term, drug delivery solutions for patients suffering from ophthalmic diseases. Its lead product candidate is SpyGlass Drug Delivery Platform with bimatoprost, which is designed to deliver three years of bimotic anti-inflammatory therapy to targeted tissues in the eye.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SPYGLASS PHARMA INC SETS IPO PRICE AT $16.00 PER SHARE
Company Overview: SPYGLASS PHARMA INC. is a pharmaceutical company involved in the development and commercialization of innovative therapies.
Stock Price Information: The current price of SPYGLASS PHARMA INC. shares is $16.00 per share.
See More
Jennifer Garner's Once Upon a Farm Sees Nearly 20% Increase as IPO Week Concludes
Jennifer Garner's Characters: Garner is known for her roles as Sidney Bristow in Alias and Elektra in Marvel films, where she faced tough adversaries.
Current Challenge: The actress is now dealing with the challenges posed by unpredictable investors in her entrepreneurial ventures.
Entrepreneurial Success: Despite the challenges, Garner appears to be successfully navigating the investment landscape.
Transition from Acting to Business: Garner's shift from acting to entrepreneurship highlights her versatility and determination in facing new challenges.
See More
SpyGlass Pharma and Agomab's Contrasting Nasdaq Debuts
- SpyGlass Pharma's Strong Performance: SpyGlass Pharma (SGP) opened at $24.00 on its Nasdaq debut, reflecting a 50% increase from its IPO price of $16.00, and surged to $26.00 during trading, indicating a 63% rise, showcasing strong market interest in its ocular treatment candidates.
- Agomab Therapeutics Decline: In contrast, Agomab Therapeutics (AGMB) opened at $14.70, representing an ~8% drop from its IPO price, and fell further to $14.00, marking a 13% decline, indicating cautious market sentiment towards its immunology and inflammatory disease treatments.
- Significant Fundraising: The two companies priced their offerings late Thursday to raise a combined total of $350 million in gross proceeds, reflecting ongoing investor interest and enthusiasm in the biotech sector.
- Market Volatility Impact: SpyGlass's stock was halted for volatility but quickly rebounded, indicating investor confidence in its growth potential, while Agomab's continued decline may affect its future fundraising and market performance.
See More
SpyGlass Pharma and Agomab IPO Pricing Announced
- SpyGlass Pharma IPO: SpyGlass Pharma (SGP) is set to begin trading on Nasdaq after pricing its IPO at $16.00 per share for 9.375 million shares, aiming to raise approximately $150 million to fund phase 3 trials for its Bimatoprost Drug Pad-IOL System, with data expected in 2027, highlighting its potential in glaucoma treatment.
- Agomab Therapeutics Offering: Belgian biotech Agomab Therapeutics (AGMB) also priced its offering at $16.00 per share for 12.5 million American Depositary Shares, targeting $200 million in gross proceeds to support a Phase 2b trial for its drug ontunisertib, aimed at treating fibrostenosing Crohn’s disease, set to begin in H2 2026.
- Positive Market Response: The combined expected proceeds of $350 million from both companies reflect strong investor interest in the biotech sector, particularly in innovative drug development for ophthalmology and gastrointestinal diseases.
- Clinical Trial Prospects: The clinical-stage candidates from SpyGlass and Agomab present significant market opportunities, as successful trials could enhance their competitiveness in the biopharmaceutical industry and attract further investment.
See More
SpyGlass Pharma Raises $150 Million in IPO for Eye Condition Treatments
- Funding Achievement: SpyGlass Pharma successfully raised $150 million by offering 9.4 million shares at $16 each, reflecting strong market interest in its chronic eye condition treatments and expected to accelerate product development.
- Core Product: The company's lead product, the BIM-IOL System, integrates novel drug pads with an intraocular lens, designed to be implanted during routine cataract surgery to reduce intraocular pressure in patients with open-angle glaucoma and ocular hypertension, showcasing significant clinical application potential.
- Technological Innovation: SpyGlass is also developing a non-IOL-based, ring-shaped sustained-release implant, aimed at providing retreatment options for patients who have received the BIM-IOL System, further expanding its market share in chronic eye conditions.
- Market Positioning: Founded in 2019, SpyGlass Pharma plans to list on Nasdaq under the symbol SGP, and this funding will enhance its competitiveness in the chronic eye condition treatment market.
See More
SpyGlass Pharma Raises $150 Million in IPO for Eye Condition Treatments
- Fundraising Success: SpyGlass Pharma successfully raised $150 million by offering 9.4 million shares at $16 each, the midpoint of the $15 to $17 range, indicating strong market demand for its innovative products and solidifying its position in the biotech sector.
- Market Valuation: Following this financing, SpyGlass Pharma commands a fully diluted market value of $549 million, reflecting investor confidence in its long-term growth potential, particularly in the chronic eye disease treatment space.
- Product Innovation: The company's lead product, the BIM-IOL System, integrates novel drug pads with an intraocular lens, designed to be implanted during routine cataract surgery to reduce intraocular pressure in glaucoma patients, showcasing its unique advantages in ophthalmic treatment.
- Future Development: SpyGlass Pharma is also developing a non-IOL-based, ring-shaped sustained-release implant, which is expected to provide ongoing treatment for patients who have undergone prior cataract surgery, further expanding its product line and enhancing market competitiveness.
See More
SPYGLASS PHARMA INC SETS IPO PRICE AT $16.00 PER SHARE
Company Overview: SPYGLASS PHARMA INC. is a pharmaceutical company involved in the development and commercialization of innovative therapies.
Stock Price Information: The current price of SPYGLASS PHARMA INC. shares is $16.00 per share.
See More
Jennifer Garner's Once Upon a Farm Sees Nearly 20% Increase as IPO Week Concludes
Jennifer Garner's Characters: Garner is known for her roles as Sidney Bristow in Alias and Elektra in Marvel films, where she faced tough adversaries.
Current Challenge: The actress is now dealing with the challenges posed by unpredictable investors in her entrepreneurial ventures.
Entrepreneurial Success: Despite the challenges, Garner appears to be successfully navigating the investment landscape.
Transition from Acting to Business: Garner's shift from acting to entrepreneurship highlights her versatility and determination in facing new challenges.
See More
SpyGlass Pharma and Agomab's Contrasting Nasdaq Debuts
- SpyGlass Pharma's Strong Performance: SpyGlass Pharma (SGP) opened at $24.00 on its Nasdaq debut, reflecting a 50% increase from its IPO price of $16.00, and surged to $26.00 during trading, indicating a 63% rise, showcasing strong market interest in its ocular treatment candidates.
- Agomab Therapeutics Decline: In contrast, Agomab Therapeutics (AGMB) opened at $14.70, representing an ~8% drop from its IPO price, and fell further to $14.00, marking a 13% decline, indicating cautious market sentiment towards its immunology and inflammatory disease treatments.
- Significant Fundraising: The two companies priced their offerings late Thursday to raise a combined total of $350 million in gross proceeds, reflecting ongoing investor interest and enthusiasm in the biotech sector.
- Market Volatility Impact: SpyGlass's stock was halted for volatility but quickly rebounded, indicating investor confidence in its growth potential, while Agomab's continued decline may affect its future fundraising and market performance.
See More
SpyGlass Pharma and Agomab IPO Pricing Announced
- SpyGlass Pharma IPO: SpyGlass Pharma (SGP) is set to begin trading on Nasdaq after pricing its IPO at $16.00 per share for 9.375 million shares, aiming to raise approximately $150 million to fund phase 3 trials for its Bimatoprost Drug Pad-IOL System, with data expected in 2027, highlighting its potential in glaucoma treatment.
- Agomab Therapeutics Offering: Belgian biotech Agomab Therapeutics (AGMB) also priced its offering at $16.00 per share for 12.5 million American Depositary Shares, targeting $200 million in gross proceeds to support a Phase 2b trial for its drug ontunisertib, aimed at treating fibrostenosing Crohn’s disease, set to begin in H2 2026.
- Positive Market Response: The combined expected proceeds of $350 million from both companies reflect strong investor interest in the biotech sector, particularly in innovative drug development for ophthalmology and gastrointestinal diseases.
- Clinical Trial Prospects: The clinical-stage candidates from SpyGlass and Agomab present significant market opportunities, as successful trials could enhance their competitiveness in the biopharmaceutical industry and attract further investment.
See More
SpyGlass Pharma Raises $150 Million in IPO for Eye Condition Treatments
- Funding Achievement: SpyGlass Pharma successfully raised $150 million by offering 9.4 million shares at $16 each, reflecting strong market interest in its chronic eye condition treatments and expected to accelerate product development.
- Core Product: The company's lead product, the BIM-IOL System, integrates novel drug pads with an intraocular lens, designed to be implanted during routine cataract surgery to reduce intraocular pressure in patients with open-angle glaucoma and ocular hypertension, showcasing significant clinical application potential.
- Technological Innovation: SpyGlass is also developing a non-IOL-based, ring-shaped sustained-release implant, aimed at providing retreatment options for patients who have received the BIM-IOL System, further expanding its market share in chronic eye conditions.
- Market Positioning: Founded in 2019, SpyGlass Pharma plans to list on Nasdaq under the symbol SGP, and this funding will enhance its competitiveness in the chronic eye condition treatment market.
See More
SpyGlass Pharma Raises $150 Million in IPO for Eye Condition Treatments
- Fundraising Success: SpyGlass Pharma successfully raised $150 million by offering 9.4 million shares at $16 each, the midpoint of the $15 to $17 range, indicating strong market demand for its innovative products and solidifying its position in the biotech sector.
- Market Valuation: Following this financing, SpyGlass Pharma commands a fully diluted market value of $549 million, reflecting investor confidence in its long-term growth potential, particularly in the chronic eye disease treatment space.
- Product Innovation: The company's lead product, the BIM-IOL System, integrates novel drug pads with an intraocular lens, designed to be implanted during routine cataract surgery to reduce intraocular pressure in glaucoma patients, showcasing its unique advantages in ophthalmic treatment.
- Future Development: SpyGlass Pharma is also developing a non-IOL-based, ring-shaped sustained-release implant, which is expected to provide ongoing treatment for patients who have undergone prior cataract surgery, further expanding its product line and enhancing market competitiveness.
See More
